Back
 
HIV PrEP Pre-Exposure Prophylaxis Articles
Additional models:
 
Feasibility of Long-Acting Injectable Cabotegravir PrEP Initiation and Administration by Community Health Workers and Early Aspects of the PrEP Injection Care Continuum in a Primary Care Center in Washington, D.C.
- (07/27/23))
 
PEP-in-pocket (PIP): Long-term follow-up of on demand HIV post-exposure prophylaxis: Is PEP-in-Pocket Best Option for Low-Frequency High-Risk HIV Exposure?
- (10/18/23))
 
Expanding PrEP by Embedding Navigators in High STI Testing Clinical Sites
- (10/18/23))
 
Engaging Black Women on Cabotegravir LA for PrEP by Optimizing Novel Implementation Strategies (EBONI) Study: Provider Perceptions of Appropriateness of Cabotegravir LA for PrEP for Cis-and-Trans Black Women
- (10/16/23))
 
Integrating Long-Acting Injectable Cabotegravir for PrEP Into Standard of Care for Cisgender Women, Transgender Women, Transgender Men, and Men Who Have Sex With Men: Results From the PILLAR & EBONI Studies
- (10/16/23))
 
At-Home vs. In-Clinic Receipt of Cabotegravir and Rilpivirine Long-Acting: An Implemtentation Science Trial
- (10/13/23))
 
---------------------------------------------------
 
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons, PURPOSE 2
- (12/06/24)
 
Glasgow:
PrEP for Women Case Discussion: On Demand 2:7 for Women Discussed
- (12/04/24)
 
Glasgow:
PrEPping for the Future: The Era of Choice
- (12/04/24)
 
Glasgow:
LEN PrEP PURPOSE-2 Twice-Yearly Gilead Glasgow Press Release
- (11/16/24)
 
Glasgow:
PrEP-Associated Stigma in Europe: Findings From a Real-World Survey
- (11/16/24)
 
Glasgow:
Cost-effectiveness and Public-Health Impact of Cabotegravir Long-Acting Injectable for HIV Pre-exposure Prophylaxis in Canada
- (11/16/24)
 
Glasgow:
PURPOSE 1 LEN PrEP Summary
- (11/16/24)
 
Glasgow:
Len LA PrEP PURPOSE 2 Summary
- (11/16/24)
 
Glasgow:
Twice-yearly lenacapavir PrEP in cisgender gay men, transgender women and men, and gender-diverse people (PURPOSE 2)
- (11/16/24)
 
Glasgow:
Annual persistence in use of twice-yearly lenacapavir versus daily oral PrEP in the PURPOSE 1 phase 3 trial
- (11/16/24)
 
ID Week:
Implementation and Uptake of Long-acting Injectable PrEP at Atlanta VA Healthcare System
- (10/24/24)
 
ID Week:
Implementation and Uptake of Long-acting Injectable PrEP at Atlanta VA Healthcare System
- (10/24/24)
 
ID Week:
Opportunities for PrEP Awareness and Engagement: A Survey among Cisgender Women Seeking Healthcare in the US
- (10/24/24)
 
ID Week:
Improving HIV Pre-exposure Prophylaxis (PrEP) among Transgender Individuals
- (10/24/24)
 
ID Week:
Integrating PrEP Services into a Gynecology Clinic in Alabama: A Qualitative Analysis of Key Determinants
- (10/24/24)
 
ID Week:
Concerns and opinions of people currently or previously on oral and long acting injectable forms of HIV preexposure prophylaxis (PrEP)
- (10/24/24)
 
ID Week:
Trajectories of Newly Initiated Pre-Exposure Prophylaxis (PrEP) Use among Priority Populations with Unmet Needs for PrEP in the USA
- (10/21/24)
 
ID Week:
Real-World Use of Cabotegravir Long-Acting for Pre-Exposure Prophylaxis: Data from Trio Health Cohort
- (10/21/24)
 
ID Week:
Missed opportunities for HIV Prevention and Treatment in People Hospitalized with Serious Injection Related Infections: The CHOICE+ Cohort
- (10/21/24)
 
ID Week:
Week 26 Interim Analysis of Implementation and Delivery of Long-Acting Injectable Cabotegravir for PrEP in a Community Pharmacy Setting
- (10/21/24)
 
ID Week:
Cabotegravir Long-Acting for Pre-Exposure Prophylaxis (PrEP): Real World Data on On-Time Dosing, HIV Testing and HIV Acquisition from the OPERA Cohort
- (10/21/24)
 
ID Week:
Social Determinants of Health and Side Effects Significantly Predict Pre-Exposure Prophylaxis (PrEP) Preferences for Every 2 Month Long-Acting Injectable vs. Daily Oral PrEP among Cisgender Women in the United States and the Dominican Republic
- (10/21/24)
 
ID Week:
Change in Healthcare Professionals' Identification, Counseling, and Adherence With Black Women for Long-Acting Cabotegravir (CAB LA) for PrEP Across Women's Health, Primary Care, and Infectious Diseases Sites: Findings From the EBONI Study
- (10/21/24)
 
ID Week:
PrEP Decision Factors: a CHORUS Healthcare Professional Survey
- (10/21/24)
 
ID Week:
Changes in Renal Function After Switching from Emtricitabine/Tenofovir Disoproxil Fumarate to Emtricitabine/Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis (PrEP): A Real-World Study
- (10/21/24)
 
ID Week:
Update on Lenacapavir for PrEP: Results from the Interim Analyses of PURPOSE 1 and PURPOSE 2
- (10/21/24)
 
ID Week:
Over 80% Adhere to Long-Acting CAB+RPV Despite Prior Non-Adherence
- Mark Mascolini (10/21/24)
 
ID Week:
People With HIV in the United States (US) Switching to Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA) From Oral Antiretroviral Therapy (ART) Have Numerous Real-World Benefits, Including High Adherence and Treatment Satisfaction
- (10/21/24)
 
ID Week:
Long-acting Injectable HIV Treatment in Individuals with Adherence Challenges:
- (10/21/24)
 
HIVR4P
The role of healthcare-related experiences in willingness and preference for long-acting injectable PrEP (LA-PrEP) among transfeminine persons in the US Transgender Women's Internet Survey and Testing (TWIST) study
- (10/16/24)
 
HIVR4P
Gap Between Oral and Injectable PrEP Awareness in US Transgender Women
- Mark Mascolini (10/16/24)
 
HIVR4P
Managing inflammation from STIs as an HIV prevention strategy Can Cutting STI-Linked Inflammation Prevent HIV Infection?
- Mark Mascolini (10/16/24)
 
HIVR4P
STI Risk Falls 80% After Milan MSM Get DoxyPEP Prescription
- Mark Mascolini (10/16/24)
 
HIVR4P
Use of HIV rapid detection tests when initiating long-acting cabotegravir for HIV prevention, within an implementation science project
- (10/16/24)
 
HIVR4P
Acceptability, adherence, preference and safety of placebo Long-Acting Pre-exposure Prophylaxis (LA-PrEP) injections and implants for HIV-prevention in South African men: the SAMURAI study
- (10/16/24)
 
HIVR4P
HIV PEP-in-Pocket ("PIP") facilitates the de-medicalization of HIV prevention
- (10/16/24)
 
HIVR4P
PrEP uptake and adherence among transgender women: findings from a randomized clinical trial of a multicomponent intervention (HPTN 091) PrEP Uptake Over 85% in Big US/Brazil Transgender Woman Study
- Mark Mascolini (10/16/24)
 
HIVR4P
Greater PrEP use in a community-based needle and syringe program versus facility-based medication for opioid use disorder program for people who use drugs in Uganda
- (10/16/24)
 
HIVR4P
PrEP choice for women in Africa: uptake of oral PrEP and PrEP ring
- (10/16/24)
 
HIVR4P
Patterns of PrEP use among women in the context of choice: early results from CATALYST, an implementation study offering oral PrEP and PrEP ring across five African countries
- (10/16/24)
 
HIVR4P
Provider and client perspectives on PrEP choice: quality of PrEP choice and factors influencing its provision in the CATALYST implementation study
- (10/16/24)
 
HIVR4P
Integration of oral and injectable PrEP services for adolescents at the community level in Sao Paulo
- (10/16/24)
 
HIVR4P
Switching between oral and injectable pre-exposure prophylaxis (PrEP) regimens in the United States: an investigation of reasons for switching in the real world
- (10/12/24)
 
HIVR4P
Early implementation of long-acting injectable cabotegravir for HIV prevention in a safety net primary care center in U.S. South at Grady in Atlanta
- (10/12/24)
 
HIVR4P
Pharmacokinetic superiority of a 3-month dapivirine vaginal ring (100 mg) compared to the 1-month dapivirine vaginal ring (25 mg)
- (10/12/24)
 
HIVR4P
Short-term combination immunotherapy with broadly neutralizing antibodies and CCR5 blockade mediates ART-free viral control in infant rhesus macaques
- (10/11/24)
 
HIVR4P
17-Clinic US Study Pinpoints Keys to Giving Long-Acting Injected PrEP: Overcoming Challenges Integrating Injectable PrEP Into Care: Key Strategies From The PILLAR Study
- Mark Mascolini (10/11/24)
 
HIVR4P
High CAB-LA PrEP On-Time and Retention Rates in US Urban Safety-Net Clinic Population. SF, Ward-86
- Mark Mascolini (10/11/24)
 
HIVR4P
Long-acting injectable Cabotegravir (CAB-LA) pilot implementation at primary healthcare level in resource-limited settings: early real-world evidence from the USAID DISCOVER-Health Project in Zambia
- (10/11/24)
 
HIVR4P
HIV pre-exposure prophylaxis (PrEP) access preference among men who have sex with men in China: a discrete choice experiment
- (10/10/24)
 
HIVR4P
Phase 1 dose-escalation trial to evaluate the safety, tolerability, pharmacokinetics and neutralization activity of PGDM1400LS in combination with VRC07-523LS and PGT121.414.LS in healthy participants without HIV (HVTN 140/HPTN 101)
- (10/10/24)
 
HIVR4P
HIV Trends in Metropolitan US Cities from 2014-2022: Baseline For The Ending The Epidemic Initiative
- (10/10/24)
 
HIVR4P
Early virologic success on ART following breakthrough infection on CAB-LA PrEP
- Mark Mascolini (10/10/24)
 
HIVR4P
Gilead Lenacapavir Access Statement & Voluntary Licensing Agreement
- (10/10/24)
 
HIVR4P
PURPOSE-2 & Other PURPOSE Studies
- (10/10/24)
 
HIVR4P
Global racial, ethnic, and gender diversity among participants enrolled in the PURPOSE-2 trial of lenacapavir for pre-exposure prophylaxis (PrEP)
- (10/10/24)
 
HIVR4P
Development of a long-acting biodegradable hydrogel injectable system for single or multi-purpose prevention of HIV and/or pregnancy
- (10/10/24)
 
HIVR4P
Safety and tolerability of oral islatravir (ISL) once-monthly (QM) as pre-exposure prophylaxis (PrEP) in cisgender men and transgender women at elevated risk for acquiring HIV-1
- (10/10/24)
 
HIVR4P
Safety and tolerability of oral islatravir (ISL) once-monthly (QM) as pre-exposure prophylaxis (PrEP) in cisgender women at elevated risk for acquiring HIV-1
- (10/10/24)
 
HIVR4P
Scaling a non-human primate physiologically-based pharmacokinetic model of extended-release MK-2048 and combination MK-2048/vicriviroc (MK-2048A) intravaginal rings into humans using phase 1 MTN-027 and MTN-028 studies
- (10/09/24)
 
HIVR4P
Weekly oral prophylaxis with MK-8527 protects rhesus macaques from rectal challenge with simian-human immunodeficiency virus
- (10/09/24)
 
HIVR4P
ViiV HEALTHCARE TO TRIPLE ANNUAL SUPPLY OF LONG-ACTING HIV PREP FOR LOW- AND MIDDLE-INCOME COUNTRIES
- (10/06/24)
 
HIVR4P
Preferences for starting daily, on-demand, and long-acting injectable HIV pre-exposure prophylaxis among transfeminine persons in the United States: results from the Transgender Women's Internet Survey and Testing (TWIST) study
- (10/06/24)
 
HIVR4P
Preferences for telePrEP among people who access HIV self-testing in Philadelphia
- (10/06/24)
 
HIVR4P
Implementing long-acting cabotegravir for HIV Pre-Exposure Prophylaxis in a large academic hospital-based urban HIV clinic
- (10/06/24)
 
HIVR4P
Examples of studies - CATALYST South Africa
- (10/06/24)
 
HIVR4P
Examples of studies - DCE results on service delivery preferences
- (10/06/24)
 
HIVR4P
Examples of studies - Project PrEP
- (10/06/24)
 
HIVR4P
Implementing PrEP Choice: Experiences from South Africa
- (10/06/24)
 
HIVR4P
History of injectable contraception was associated with women's willingness to use long-acting injectable PrEP: findings from US women across nine cities
- (10/06/24)
 
HIVR4P
Characterizing the Levels of Knowledge, Attitudes, and Behaviors Regarding the Use and Risks Associated with Oral HIV-1 Pre-Exposure Prophylaxis (PrEP) Among People Prescribed PrEP in Canada
- (10/06/24)
 
HIVR4P
Understanding preferences for pre-exposure prophylaxis (PrEP) among people who would benefit from PrEP in the United States
- (10/06/24)
 
HIVR4P
Interest in long-acting PrEP modalities among women in the United States with a history of injectable medication use: findings from the MACS/WIHS combined cohort study
- (10/06/24)
 
HIVR4P
Safety, Pharmacokinetics, and Degradation of Ultra-Long-Acting Injectable, Biodegradable, and Removable In-Situ Forming Implant with Cabotegravir for HIV Prevention
- (10/06/24)
 
Latino PrEP Barriers "Why Not Just go on PrEP?": A Study to Inform Implementation of an HIV Prevention Intervention Among Hispanic/Latino Men Who Have Sex With Men in the Northeastern United States
- (09/09/24)
 
IAS:
The DoxyPEP Debate: To DoxyPEP or not to DoxyPEP?
- (08/26/24)
 
IAS:
Phase 1, open-label study to evaluate the drug interaction between MK-8527, an HIV-1 nucleoside reverse transcriptase translocation inhibitor, and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females
- (08/06/24)
 
IAS:
Long-acting oral PrEP is preferred to injections: findings from an online sample of American gay, bisexual, and other men who have sex with men
- (08/06/24)
 
IAS:
Early experiences with usage of injectable cabotegravir (CAB-LA) among Kenyan and Ugandan adults participating in the SEARCH Dynamic Choice HIV Prevention trial: a qualitative study....self & external stigma, convenience, feeling healthy
- (08/03/24)
 
IAS:
Pre-Exposure Prophylaxis product choice of participants in HPTN 083
- (08/03/24)
 
IAS:
Changes in sexual behavior among adolescent girls receiving long-acting injectable cabotegravir for HIV prevention: the HPTN 084-01 study
- (08/03/24)
 
IAS:
CAB-LA for PrEP Earns High Satisfaction Rates (90%) in Rural Kenya and Uganda
- Mark Mascolini (08/03/24)
 
IAS:
(Implants) Preference for long-acting HIV prevention methods among transgender women at greatest risk for HIV acquisition in eastern and southern United States: findings from the LITE cohort
- (08/02/24)
 
IAS:
Preference for long-acting HIV prevention methods among transgender women at greatest risk for HIV acquisition in eastern and southern United States: findings from the LITE cohort
- (08/01/24)
 
Dolutegravir with recycled nucleoside reverse transcriptase inhibitors maintains better viral suppression than protease inhibitor based antiretroviral therapy over 144 weeks: VISEND Trial
- (08/01/24)
 
IAS:
Influencers and Decision-Making Factors for Choosing Injectable PrEP Among Men Who Have Sex With Men and Transgender Men in the United States
- (08/01/24)
 
IAS:
Location preferences for accessing long-acting injectable pre-exposure prophylaxis (LA-PrEP) among men who have sex with men (MSM) in the U.S currently using daily-oral PrEP
- (08/01/24)
 
IAS:
Need for Improved HIV Testing Prior to and During Pre-Exposure Prophylaxis with Cabotegravir Long-Acting Injections in Routine Clinical Care in the United States: Low Rates of HIV Tesing
- (08/01/24)
 
IAS:
Only 9% PrEP Use Among Transfeminine Persons: HIV pre-exposure prophylaxis awareness, willingness, and use among transfeminine persons with high likelihood of HIV in the United States: results from the Transgender Women's Internet Survey and Testing (TWIST)
- (08/01/24)
 
IAS:
"The simplest way to go:" A mixed methods analysis of why women who inject drugs selected long-acting injectable cabotegravir instead of daily oral PrEP.....95% of women initiated CAB Lai PrEP !!!
- (07/31/24)
 
IAS:
Increased cardiovascular risk in perinatally HIV-acquired adolescents (PHIV) may linked to proinflammatory NK cells
- (07/31/24)
 
IAS:
Real-World Adherence of HIV-1 Oral Pre-Exposure Prophylaxis Regimens in the USA: A Group-Based Trajectory Modeling Approach
IAS:
Initial evaluation of injectable cabotegravir (CAB-LA) safety during pregnancy in the HPTN 084 open-label extension
- (07/30/24)
 
IAS:
Long-acting injectable cabotegravir for HIV prevention is safe in pregnancy
- (07/30/24)
 
IAS:
Doxycycline PrEP prevents STIs without affecting vaginal bacterial flora in female sex workers in Tokyo
- (07/28/24)
 
IAS:
Evaluation of long-acting cabotegravir (CAB-LA) pharmacokinetics during pregnancy: a sub-study analysis of the HPTN 084 open label extension study
- (07/28/24)
 
IAS:
High Interest in LA PrEP Among MSM in Europe Survey - Intention to use long-acting PrEP among MSM in Europe -results from the PROTECT survey from Spain, Italy, Germany, France and the United Kingdom
- (07/28/24)
 
IAS:
STI testing rates among PrEP users randomized to 3-monthly (standard of care) or 6-monthly monitoring within the EZI-PrEP trial, the Netherlands: preliminary results - no difference in STIs between 6 vs 3 months visits
- (07/28/24)
 
IAS:
Knowledge, awareness, feasibility, and acceptability of long-acting Cabotegravir for HIV prevention: results from the SEARCH Dynamic Choice HIV prevention trial
- (07/28/24)
 
IAS:
Centering Community Leadership with PURPOSE: Inclusion of Adolescents, Cisgender Women, and Pregnant and Lactating Individuals in a Phase 3 Clinical Trial Evaluating Lenacapavir and Emtricitabine/Tenofovir Alafenamide for PrEP
- (07/28/24)
 
IAS:
Twice-Yearly Lenacapavir or Daily Emtricitabine/Tenofovir Alafenamide for HIV Prevention in Cisgender Women: Interim Analysis Results from the PURPOSE 1 Study
- (07/28/24)
 
IAS:
DoxyPrEP Cuts STI Rate in FSW Without Fueling Other Infections
- Mark Mascolini (07/27/24)
 
IAS:
A pilot, randomized controlled trial of doxycycline pre-exposure prophylaxis versus placebo for prevention of bacterial sexually transmitted infections in men who have sex with men living with HIV
- (07/27/24)
 
IAS:
Antimicrobial resistance (AMR) in Neisseria gonorrhoeae (GC) infections among MSM on Doxycycline post-exposure prophylaxis.
- (07/24/24)
 
The relationship between anti-LGBTQ+ legislation and HIV prevention among sexual and gender minoritized youth
- (05/23/24)
 
Impact of HIV pre-exposure prophylaxis prescriptions on HIV diagnoses in New York city: disparities in new HIV diagnosis
- (05/23/24)
 
EuroHIV-HepMtg2024: Acute Hepatitis B Infections after Reducing ART among Vaccinated Patients Living with HIV: HBV "PrEP-effect" of TDF/FTC?
- (05/23/24)
 
Feasibility of Implementing a Low-Barrier Long-Acting Injectable Antiretroviral Program for HIV Treatment & Prevention for People Experiencing Homelessness
- (04/03/24)
 
CROI:
EHE "May not be feasible in many US cities" - Charting Achievable Milestones for HIV Care Enhancement and Prevention in the US Through 2035
- (04/02/24)
 
CROI:
First Case of HIV Seroconversion With Emergence of InSTI Resistance on CAB-LA PrEP in Routine Care
- (04/02/24)
 
CROI:
HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women
- (04/02/24)
 
CROI:
A Randomized Trial Switching Adults ≥ 60 Years Old From First-Line ART to B/F/TAF: Week 48 Results
- (03/28/24)
 
CROI:
Cabotegravir Population Pharmacokinetic Analysis of Adults & Adolescents Living with HIV or at Risk for HIV Receiving PrEP
- (03/27/24)
 
CROI:
Why Is Cabotegravir Rollout So Slow?
- (03/27/24)
 
CROI:
HIV Post-exposure Prophylaxis (PEP) Prescription Trends (underutilized) - United States, 2013-2022
- (03/27/24)
 
CROI:
PEP2PrEP: an effective HIV risk-reduction strategyn
- (03/27/24)
 
CROI:
Randomized Trial Shows Huge Uptake Success of HIV Prevention Choices in Kenya, Uganda
- (03/22/24)
 
CROI:
US States With More PrEP Coverage See Bigger Drops in HIV Diagnoses
- Mark Mascolini (03/18/24)
 
CROI:
Safety Study of Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Early Pregnancy
- (03/18/24)
 
CROI:
Strong Oral PrEP Uptake and Persistence in 3000 African Girls and Young Women in INSIGHT Cohort
- Mark Mascolini (03/18/24)
 
CROI:
< HIV Incidence in Users of HIV Preexposure Prophylaxis in Australia: A Whole-of-Population Analysis
- (03/18/24)
 
CROI:
HIV incidence in users of HIV preexposure prophylaxis in Australia: a whole-of-population analysis
- Mark Mascolini (03/18/24)
 
CROI:
Associations between a polygenic risk score for Alzheimer's disease and brain integrity in HIV
- (03/18/24)
 
CROI:
Doxy-PEP Associated with Declines in Chlamydia and Syphilis in MSM and Trans Women in San Francisco.....increase in gonorrhea after SF Guidelines Oct 2022
- (03/18/24)
 
CROI:
Doxy-PEP Effectiveness in Men Who Have Sex with Men (MSM) and Transgender Women (TGW) on HIV PrEP
- (03/18/24)
 
CROI:
Doxycycline Post-Exposure Prophylaxis (DoxyPEP): High uptake and Significant Decline in STIs after Clinical Implementation
- (03/18/24)
 
CROI:
Randomized Trial Shows Huge Uptake Success of HIV Prevention Choices in Kenya, Uganda
- Mark Mascolini (03/18/24)
 
CROI:
Phone calls for PrEP persistence in Kenyan women in postabortal care: a cluster randomized trial.
- Mark Mascolini (03/12/24)
 
CROI:
PrEP Non-Persistence and New HIV Diagnoses: A Real-World Analysis of >120,000 People Prescribed PrEP
- (03/12/24)
 
CROI:
Safety of dapivirine vaginal ring and oral PrEP for HIV prevention in the second trimester.
- Mark Mascolini (03/12/24)
 
CROI:
CHANGES IN HIV PREP AWARENESS & USE AMONG PWID IN 19 U.S. CITIES, 2018 & 2022 ....very low PrEP use
- (03/12/24)
 
CROI:
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: HPTN 083
- (03/12/24)
 
CROI:
Healthcare Staff Acceptability and Feasibility of Telehealth Delivery of Cabotegravir for PrEP
- (03/12/24)
 
CROI:
Interest in Long-Acting Injectable PrEP Among Transgender Women in the United States
- (03/12/24)
 
CROI:
Real-World Use of Cabotegravir Long-Acting for Preexposure Prophylaxis: Trio Health Cohort
- (03/12/24)
 
CROI:
Preexposure Prophylaxis With Cabotegravir Long-Acting Injectable in the OPERA Cohort
- (03/12/24)
 
CROI:
No Virologic Failures, Good Safety With LA I njected CAB + RPV for Adolescents IMPAACT 2017 MOCHA Study
- Mark Mascolini (03/11/24)
 
CROI:
High PrEP uptake and adherence with point of care tenofovir testing among young African women: Results from the INSIGHT cohort
- (03/07/24)
 
CROI:
Final Results of ANRS 174 DOXYVAC: A Randomized trial to Prevent STIs in MSM on PrEP
- (03/07/24)
 
HIV Prevention Doubles PrEP Use: auto text messaging+mobile web-app peer support+non-maulaized telehealth coaching by paraprofessionals
- (02/27/24)
 
HIV pre-exposure prophylaxis provision by U.S. health centers in 2021
- (02/02/24)
 
LAI PrEP Barriers & Facilitators US Primary Care Setting
- (01/29/24)
 
Lenacapavir Safety - Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial
- (01/29/24)
 
Lenacapavir 5 PrEP Global Studies
- (01/29/24)
 
CROI:
ULTRA LONG-ACTING REFILLABLE ISLATRAVIR IMPLANT FULLY PROTECTS NHP AGAINST SHIV
 
CROI:
Vaginal PrEP Efficacy of Biodegradable Islatravir Implants in Macaques Islatravir Implant Protects Macaques From Vaginal SHIV Infection
- (02/24/23)
 
5 Purpose Studies for Lanacapavir PrEP: Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
- (01/10/24)
 
Exploring barriers and facilitators to PrEP use among transgender women in two urban areas: implications for messaging and communication
- (01/10/24)
 
Out-of-pocket cost increase could put HIV prevention medications out of reach
- (01/10/24)
 
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial
- (01/10/24)
 
Brief Report: Outcomes of Individuals Using HIV Postexposure Prophylaxis-In-Pocket ("PIP") for Low-Frequency, High-Risk Exposures in Toronto, Canada
- (01/10/24)
 
TelePrEP in NYC
- (01/10/24)
 
Patient and Provider Perspectives on a Novel, Low-Threshold HIV PrEP Program for People Who Inject Drugs Experiencing Homelessness
- (01/10/24)
 
PrEP Use and HIV Incidence Among Youth At-Risk for HIV Infection in Los Angeles and New Orleans: Findings From ATN 149
- (01/10/24)
 
Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants
- (01/10/24)
 
Preexposure Prophylaxis Use History in People With Antiretroviral Resistance at Human Immunodeficiency Virus (HIV) Diagnosis: Findings From New York City HIV Surveillance and Partner Services, 2015-2022
- (01/10/24)
 
HHS EHE (PrEP) Leaders Reflect on 2023 and Look Ahead to 2024
- (01/09/24)
 
Understanding Psychosocial Determinants (Beliefs, Attitudes) of PrEP Uptake Among Cisgender Women Experiencing Heightened HIV Risk: Implications for Multi-Level Communication Intervention
- (01/09/24)
 
Advancing the community plan to end the HIV Epidemic in Philadelphia: a qualitative descriptive evaluation of low-threshold PrEP services in sexual health clinics
- (01/09/24)
 
2 Studies on PrEP for Women IDUs, Demonstrate PrEP is a Necessary Tool for Women, to EtE
- (01/09/24)
 
Aging-Related Comorbidity Burden Among Women and Men With or At-Risk for HIV in the US, 2008-2019
- (01/08/24)
 
Prioritising the values of potential users to promote uptake of HIV pre-exposure prophylaxis
- (01/08/24)
 
Person-centered HIV PrEP for cisgender women
- (01/08/24)
 
Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women
- (01/08/24)
 
Cocaine Eats Up Brain Twice as Fast as Normal Aging
- (01/08/24)
 
Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence
- (01/08/24)
 
Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts
- (01/08/24)
 
ID Week:
Update on PrEP Knowledge and Attitudes Among Adults Attending Public Health Clinics in Southern Arizona
- (10/24/22)
 
ID Week :
Healthcare Staff Perceptions of Feasibility and Acceptability on Implementing Injectable HIV Pre-exposure Prophylaxis Into Standard of Care: Baseline Results From the PrEP Implementation Study for Cabotegravir Long Acting for Men in the Real World (PILLAR)
- (10/16/23)
 
ID Week:
High PrEP Awareness in US Women, But Only 20% Ever Used It
- Mark Mascolini (10/23/22)
 
ID Week :
Increase in New HIV Diagnoses Following Decrease in Use of Pre-exposure Prophylaxis (PrEP) During the COVID-19 Pandemic
- (10/16/23)
 
Feasibility of Long-Acting Injectable Cabotegravir PrEP Initiation and Administration by Community Health Workers and Early Aspects of the PrEP Injection Care Continuum in a Primary Care Center in Washington, D.C.
- (07/27/23)
 
Presence of mental health concerns is associated with poor adherence in people taking pre-exposure prophylaxis in real-world clinical practice in the United States
- (10/18/23)
 
Engaging Black Women on Cabotegravir LA for PrEP by Optimizing Novel Implementation Strategies (EBONI) Study: Provider Perceptions of Appropriateness of Cabotegravir LA for PrEP for Cis-and-Trans Black Women
- (10/16/23)
 
I
Integrating Long-Acting Injectable Cabotegravir for PrEP Into Standard of Care for Cisgender Women, Transgender Women, Transgender Men, and Men Who Have Sex With Men: Results From the PILLAR & EBONI Studies
- (10/16/23)
 
ID Week :
Exploring Cisgender Women's HIV Pre-Exposure Prophylaxis (PrEP) Needs and Preferences Across Settings: the Role of Social-Structural Factors
- (10/16/23)
 
ID Week :
Risk Factors, Risk Perception, and Long-Acting PrEP Awareness and Interest Among US Women: A National Survey
- (10/16/23)
 
ID Week :
Healthcare Staff Perceptions of Feasibility and Acceptability on Implementing Injectable HIV Pre-exposure Prophylaxis Into Standard of Care: Baseline Results From the PrEP Implementation Study for Cabotegravir Long Acting for Men in the Real World (PILLAR)
- (10/16/23)
 
ID Week :
Acceptability of an HIV Pre-Exposure Prophylaxis (PrEP) Shared Decision-Making Tool (SDT) for Diverse Populations and Healthcare Providers
- (10/13/23)
 
At-Home vs. In-Clinic Receipt of Cabotegravir and Rilpivirine Long-Acting: An Implemtentation Science Trial
- (10/13/23)
 
The First Ten Years of HIV Preexposure Prophylaxis Use and Missed Opportunities at an Urban Academic Children's Hospital
- (10/18/23)
 
PEP-in-pocket (PIP): Long-term follow-up of on demand HIV post-exposure prophylaxis: Is PEP-in-Pocket Best Option for Low-Frequency High-Risk HIV Exposure?
- (10/18/23)
 
Only Half Prescribed CAB PrEP Get at Least 1 Shot in US Outpatient Network
- (10/18/23)
 
Expanding PrEP by Embedding Navigators in High STI Testing Clinical Sites
- (10/18/23)
 
Investing in National HIV PrEP Preparedness (Over-the-Counter free PrEP)
- (09/28/23)
 
Free the PrEP - Over-the-Counter Access to HIV Preexposure Prophylaxis
- (08/11/23)
 
IAS:
PrEP Equity by sex and age, United States, 2012-2021
- (08/14/23)
 
Barriers and Facilitators to PrEP Initiation and Adherence Among Transgender and Gender Non-Binary Individuals in Southern California
 
ID Week:
Predicted uptake of novel HIV treatment options in the United States
- (10/16/23)
 
ID Week :
Factors driving decisions in the use of HIV Pre-Exposure Prophylaxis: Data from a real-world study in the United States
- (10/16/23)
 
ID Week :
The Real-World Impact of Pre-Exposure Prophylaxis (PrEP) Prescription Uptake and Dispensing Status on HIV Infection Risk in the US
- (10/16/23)
 
ID Week :
Evaluating Pre-Exposure Prophylaxis Use in a Large Integrated Rural US Health System
- (10/16/23)
 
ID Week :
Facilitators and Barriers to Engaging in PrEP and Gender Affirming Therapy for Black and Latina Transgender Women in South Florida
- (10/16/23)